GlassScriptPhysician profile
Matthew Robert Vajen
NPI 1881935294
$2,775.07
in general payments reported to CMS, 2019-2025
14 companies · $43.19 in 2025
The $43.19 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $1,187 · 2021: $363 · 2022: $390 · 2023: $214 · 2024: $89.04 · 2025: $43.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,834.33 | 2019-2025 | Audion Et Dilation System |
| Intersect Ent, INC. | $271.70 | 2019-2020 | |
| Aerin Medical INC. | $117.28 | 2019-2020 | |
| Genzyme Corporation | $111.17 | 2022-2023 | |
| Alk-Abello, INC | $92.84 | 2019-2024 | Alternaria Tenuis, Standardized Mite D. Farinae, Timothy, Standardized |
| Optinose US, INC. | $82.91 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $68.28 | 2023 | Dupixent |
| Acera Surgical, INC. | $63.42 | 2024-2025 | Restrata Wound Matrix |
| Cochlear Americas | $39.16 | 2024 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Kaleo, INC. | $32.41 | 2021-2022 | |
| Baxter Healthcare | $18.32 | 2019 | |
| Phadia US INC. | $16.60 | 2022 | |
| Hikma Pharmaceuticals USA | $15.00 | 2023 | Ryaltris |
| Merck Sharp & Dohme LLC | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Vajen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.